Spero Therapeutics announced on October 2, 2024, the publication of data from its Phase 1 clinical trial in Antimicrobial Agents and Chemotherapy. The study assessed the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, following oral administration to healthy volunteers.
The published data indicated that SPR719 demonstrated significant lung uptake and enhanced concentrations in the pulmonary epithelial lining fluid and alveolar macrophages. These compartments are crucial for targeting mycobacteria in Nontuberculous Mycobacterial-Pulmonary Disease (NTM-PD).
This positive outcome suggests SPR720's potential as an effective oral therapy for NTM lung disease. The company is exploring the potential of SPR720 as a treatment for this condition, which currently has limited treatment options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.